Bibliographic Details
| Title: |
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer |
| Authors: |
Leiby Benjamin, Alagkiozidis Ioannis, Zhang Lin, Mohamed-Hadley Alisha, Krafty Robert T, Holtz David O, Guo Wensheng, Gimotty Phyllis A, Coukos George |
| Source: |
Journal of Translational Medicine, Vol 6, Iss 1, p 2 (2008) |
| Publisher Information: |
BMC, 2008. |
| Publication Year: |
2008 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
Medicine |
| More Details: |
Abstract Because of its low toxicity, low-dose (LD) chemotherapy is ideally suited for combination with antiangiogenic drugs. We investigated the impact of tumor vascular endothelial growth factor A (VEGF-A) expression on the efficacy of LD paclitaxel chemotherapy and its interactions with the tyrosine kinase inhibitor SU5416 in the ID8 and ID8-Vegf models of ovarian cancer. Functional linear models using weighted penalized least squares were utilized to identify interactions between Vegf, LD paclitaxel and antiangiogenic therapy. LD paclitaxel yielded additive effects with antiangiogenic therapy against tumors with low Vegf expression, while it exhibited antagonism to antiangiogenic therapy in tumors with high Vegf expression. This is the first preclinical study that models interactions of LD paclitaxel chemotherapy with antiangiogenic therapy and tumor VEGF expression and offers important lessons for the rational design of clinical trials. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1479-5876 |
| Relation: |
http://www.translational-medicine.com/content/6/1/2; https://doaj.org/toc/1479-5876 |
| DOI: |
10.1186/1479-5876-6-2 |
| Access URL: |
https://doaj.org/article/508f59e9e54d44779fb2184e3f4dc1d3 |
| Accession Number: |
edsdoj.508f59e9e54d44779fb2184e3f4dc1d3 |
| Database: |
Directory of Open Access Journals |
